NuCana plc (NCNA) Balance Sheet

The downward trajectory of total assets suggests that the company is consuming its capital base to sustain R&D activities, which may limit its future strategic flexibility. Investors should monitor whether the current asset base can support the necessary clinical trial milestones before further capital raises become mandatory.

While the current ratio appears superficially high, it is heavily influenced by the timing of clinical vendor payments and does not account for the high, ongoing burn rate inherent in oncology drug development. The reliance on cash reserves to fund operations suggests that liquidity could deteriorate rapidly if trial enrollment or regulatory timelines face unexpected delays.

The significant deficit in retained earnings highlights the high-risk nature of the company's business model, where shareholder equity is primarily a function of capital raises rather than internally generated value. This structure suggests that existing shareholders face a high risk of dilution should the company need to replenish its equity base to continue operations.